The net profit of Fortis Healthcare Limited rose 84% in the third quarter of the financial year, defeating the estimates of analysts.
According to an exchange filing on Friday, the company posted a consolidated lower line of Rs 248 crore in the quarter ended December 31, 2024 as compared to Rs 135 crore in the same period in the last financial year. This compares an unanimous estimate of Rs 179 crore from analysts tracked by Bloomberg.
Fortis Q3 FY25 Highlights (Integrated, Yoy)
-
Revenue up to Rs 1,928 crore to Rs 1,680 crore (Bloomberg estimated Rs 1,884 crore).
-
Ebitda 32% up to Rs 375 crore vs. Rs 284 crore (estimated at Rs 371 crore).
-
The Ebitda margin spreads up to 19.5% vs. 16.9% (estimated at 19.7%).
-
Pure profit profit of Rs 84% ​​to Rs 248 crore vs. Rs 135 crore (estimated at Rs 179 crore).
The hospital trading experienced revenue growth in the quarter, which increased average revenue in average revenue per occupied bed and increased by 6.2% in occupied beds.
International patient revenue saw an increase of 17%, which reached Rs 132 crore in the quarter under review from Rs 113 crore in the same period last year, contributing 7.7% to the trade revenue of the overall hospital. The amount of major surgical processes, especially in neurocains and robotic surgery, increased in 23% and 77% year-to-year respectively.
Revenue from digital channels including website, mobile application and digital campaigns increased 36% year-on-year, account of 29.9% of the total hospital’s revenue.
Fortis Healthcare shares closed at Rs 650.15 at 0.15% lower on NSE, compared to a decline of 0.18% in benchmark Nifty 50. The stock has increased by 43.71% in the last 12 months.
According to Bloomberg data, 14 of the 15 analysts monitoring the company maintains a ‘buy’ rating on stock and recommends a ‘cell’. The average of the price goals of 12 -month analysts is a potential opposite of 9.2%.
Read more on earning by NDTV profit. (Tagstotranslet) Fortis Healthcare Limited (T) Income
